Menengai’s Broken Promise: How Kenya’s Geothermal Model Lost the Steam Thematic image of the Olkaria Geothermal Field Kenya’s Menengai geothermal project was sold as a model of modern public-private partnership. The state would carry the difficult and expensive burden of geothermal exploration and drilling. Private power producers would then build, own and operate power plants. Geothermal Development Company would supply the steam; the independent power producers would convert it into electricity; Kenya Power would buy the output. On paper, the arrangement was elegant. In practice, Menengai has exposed a far more uncomfortable reality: Kenya’s public steam-supply model is not delivering the certainty it promised. Menengai Phase I was designed to produce 105 megawatts from three 35 MW plants. GDC’s own project page says the three plants were awarded to Globeleq Menengai Geothermal, Sosian Menengai Geothermal Power and OrPower Twenty Two under a build-own-operate structure. Yet the ...
In the realm of medical advancements, nanotechnology has emerged as a game-changer, offering revolutionary approaches to both heart disease treatment and prevention. As we venture into 2023, nanotechnology is making remarkable strides, shaping the landscape of cardiovascular health. Let's explore two significant ways nanotechnology is transforming heart disease management and the companies leading these breakthroughs. 1. Targeted Drug Delivery: One of the remarkable ways nanotechnology is revolutionizing heart disease treatment lies in targeted drug delivery. Nanoparticles, at a scale of billionths of a meter, can be engineered to transport drugs directly to affected areas of the heart, ensuring precise delivery and minimizing side effects. This approach enhances the efficacy of medications while reducing potential harm to healthy tissues. CompanySpotlight: NanoCardio Therapeutics NanoCardio Therapeutics, a trailblazing company, is at the forefront of targeted drug delivery for he...